Press Releases

AVROBIO Announces Closing of Underwritten Public Offering

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 24, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock.

Nov 24, 2020

AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 19, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share.

Nov 19, 2020

AVROBIO Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 19, 2020-- AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in an underwritten public offering.

Nov 19, 2020

AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

Three months post-gene therapy, first patient in Gaucher trial shows reductions in the toxic metabolite plasma lyso-Gb1 and plasma chitotriosidase as compared to baseline when the patient was on ERT Ongoing Fabry disease trials continue to demonstrate sustained durability, with first patient out

Nov 17, 2020

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 6, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Nov 06, 2020

AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update

Expanded ex vivo lentiviral gene therapy pipeline with program for Hunter syndrome Received orphan drug designation from the European Commission for two lead programs, AVR-RD-01 for Fabry disease and AVR-RD-02 for Gaucher disease type 1 Clinical and pipeline updates to be shared at Virtual R&D Day

Nov 05, 2020

AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑01, an Investigational Gene Therapy for Fabry Disease

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 29, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-01, the

Oct 29, 2020

AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D Day

Event to be webcast on Tuesday, Nov. 17, 2020 at 9:00 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 26, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will host a Virtual

Oct 26, 2020

AVROBIO Appoints Dr. Gail Farfel to its Board of Directors

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 21, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Gail M. Farfel , Ph.D., to its Board of Directors. Dr.

Oct 21, 2020

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2020-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to

Oct 06, 2020



Displaying 1 - 10 of 44

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.